People: Dendreon Corp (DNDN.O)

DNDN.O on Nasdaq

2.68USD
11:24am EDT
Price Change (% chg)

$-0.01 (-0.37%)
Prev Close
$2.69
Open
$2.69
Day's High
$2.73
Day's Low
$2.66
Volume
631,269
Avg. Vol
3,435,132
52-wk High
$5.38
52-wk Low
$2.23

Search Stocks

Watson, Douglas 

Brief Biography

Mr. Douglas G. Watson has been appointed as Lead Independent Director of Dendreon Corporation, effective January 31, 2012. Mr. Watson has served as a member of the Board of Directors since February 2000. Mr. Watson is Chief Executive Officer of Pittencrieff Glen Associates, a consulting firm that he founded in July 1999. From January 1997 to May 1999, Mr. Watson served as President and Chief Executive Officer of Novartis Corporation, the U.S. subsidiary of Novartis AG. From April 1996 to December 1996, Mr. Watson served as President and Chief Executive Officer of Ciba-Geigy Corporation, which merged into Novartis Corporation in December 1996. Mr. Watson’s career spanned 33 years with Novartis, having joined Geigy (UK) Ltd. in 1966. Mr. Watson also currently serves as Chairman of OraSure Technologies, Inc., a medical diagnostics company, and as a director of Delcath Systems, Inc., a specialty pharmaceutical and medical device company. Mr. Watson previously served on the Board of Directors of BioMimetic Therapeutics, Inc., a biotechnology company, from 1999 to March 2013, Genta Incorporated, a biopharmaceutical company, from 2002 to January 2011, Javelin Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2010, and Engelhard Corporation, a surface and materials science company, from 1991 to 2006. Mr. Watson received an M.A. in Pure Mathematics from Churchill College, Cambridge University and holds an ACMA qualification as an Associate of the Chartered Institute of Management Accountants.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Search Stocks